17β-Hydroxyestra-4,9,11-trien-3-one (Trenbolone) preserves bone mineral density in skeletally mature orchiectomized rats without prostate enlargement

Bone

Volumn 51, Issue 4, 2012, Pages 667-673

  McCoy, Sean C ^a,b   Yarrow, Joshua F ^a,b   Conover, Christine F ^a   Borsa, Paul A ^b   Tillman, Mark D ^b   Conrad, Bryan P ^b   Pingel, Jennifer E ^b   Wronski, Thomas J ^b   Johnson, Sally E ^b   Kristinsson, Hordur G ^b   Ye, Fan ^b   Borst, Stephen E ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

5 Alpha reductase; Anabolic steroid; Androgen; Bone; Testosterone

Indexed keywords

ANDROGEN; BIOLOGICAL MARKER; HEMOGLOBIN; TESTOSTERONE ENANTATE; TRENBOLONE;

ANDROGEN BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY MASS; BONE DENSITY; BONE MATURATION; BONE STRENGTH; BONE TURNOVER; CONTROLLED STUDY; DIAPHYSIS; DOSE RESPONSE; DRUG EFFECT; DRUG MEGADOSE; FEMUR NECK; HEMOGLOBIN DETERMINATION; KIDNEY MASS; LOW DRUG DOSE; MALE; METAPHYSIS; MUSCLE MASS; NONHUMAN; ORCHIECTOMY; ORGAN SIZE; OSTEOLYSIS; PROSTATE; RAT; TRABECULAR BONE;

ANABOLIC AGENTS; ANDROGENS; ANIMALS; BIOLOGICAL MARKERS; BIOMECHANICS; BODY WEIGHT; BONE DENSITY; FEMUR; HEMOGLOBINS; KIDNEY; MALE; ORCHIECTOMY; ORGAN SIZE; PROSTATIC HYPERPLASIA; RATS; RATS, INBRED F344; TRENBOLONE ACETATE;

EID: 84864960916     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2012.07.008     Document Type: Article

References (57)

1. Compston J.E. Sex steroids and bone. Physiol Rev 2001, 81(1):419-447.
2. Shuler F.D., Conjeski J. Defining bone health and fracture risk in West Virginia: the World Health Organization FRAX assessment tool. W V Med J 2011, 107(5):12-17.
3. Johnell O., Kanis J.A. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 2006, 17(12):1726-1733.
4. Bass E., French D.D., Bradham D.D., Rubenstein L.Z. Risk-adjusted mortality rates of elderly veterans with hip fractures. Ann Epidemiol 2007, 17(7):514-519.
5. Rao S.S., Budhwar N., Ashfaque A. Osteoporosis in men. Am Fam Physician 2010, 82(5):503-508.
6. Leifke E., Korner H.C., Link T.M., Behre H.M., Peters P.E., Nieschlag E. Effects of testosterone replacement therapy on cortical and trabecular bone mineral density, vertebral body area and paraspinal muscle area in hypogonadal men. Eur J Endocrinol 1998, 138(1):51-58.
7. Martin A.C. Osteoporosis in men: a review of endogenous sex hormones and testosterone replacement therapy. J Pharm Pract 2011, 24(3):307-315.
8. Borst S.E., Conover C.F. Orchiectomized Fischer 344 male rat models body composition in hypogonadal state. Life Sci 2006, 79(4):411-415.
9. Borst S.E., Conover C.F., Carter C.S., Gregory C.M., Marzetti E., Leeuwenburgh C., et al. Anabolic effects of testosterone are preserved during inhibition of 5alpha-reductase. Am J Physiol Endocrinol Metab 2007, 293(2):E507-E514.
10. Borst S.E., Lee J.H., Conover C.F. Inhibition of 5alpha-reductase blocks prostate effects of testosterone without blocking anabolic effects. Am J Physiol Endocrinol Metab 2005, 288(1):E222-E227.
11. Yarrow J.F., Conover C.F., Purandare A.V., Bhakta A.M., Zheng N., Conrad B., et al. Supraphysiological testosterone enanthate administration prevents bone loss and augments bone strength in gonadectomized male and female rats. Am J Physiol Endocrinol Metab 2008, 295(5):E1213-E1222.
12. Calof O.M., Singh A.B., Lee M.L., Kenny A.M., Urban R.J., Tenover J.L., et al. Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci 2005, 60(11):1451-1457.
13. Mohler M.L., Bohl C.E., Jones A., Coss C.C., Narayanan R., He Y., et al. Nonsteroidal selective androgen receptor modulators (SARMs): dissociating the anabolic and androgenic activities of the androgen receptor for therapeutic benefit. J Med Chem 2009, 52(12):3597-3617.
14. Rosen J., Negro-Vilar A. Novel, non-steroidal, selective androgen receptor modulators (SARMs) with anabolic activity in bone and muscle and improved safety profile. J Musculoskelet Neuronal Interact 2002, 2(3):222-224.
15. Yarrow J.F., Conover C.F., McCoy S.C., Lipinska J.A., Santillana C.A., Hance J.M., et al. 17beta-Hydroxyestra-4,9,11-trien-3-one (trenbolone) exhibits tissue selective anabolic activity: effects on muscle, bone, adiposity, hemoglobin, and prostate. Am J Physiol Endocrinol Metab 2011, 300(4):E650-E660.
16. Bauer E.R., Daxenberger A., Petri T., Sauerwein H., Meyer H.H. Characterisation of the affinity of different anabolics and synthetic hormones to the human androgen receptor, human sex hormone binding globulin and to the bovine progestin receptor. APMIS 2000, 108(12):838-846.
17. Wilson V.S., Lambright C., Ostby J., Gray L.E. In vitro and in vivo effects of 17beta-trenbolone: a feedlot effluent contaminant. Toxicol Sci 2002, 70(2):202-211.
18. Gonzalez J.M., Carter J.N., Johnson D.D., Ouellette S.E., Johnson S.E. Effect of ractopamine-hydrochloride and trenbolone acetate on longissimus muscle fiber area, diameter, and satellite cell numbers in cull beef cows. J Anim Sci 2007, 85(8):1893-1901.
19. Parr S.L., Chung K.Y., Galyean M.L., Hutcheson J.P., DiLorenzo N., Hales K.E., et al. Performance of finishing beef steers in response to anabolic implant and zilpaterol hydrochloride supplementation. J Anim Sci 2011, 89(2):560-570.
20. Parr S.L., Chung K.Y., Hutcheson J.P., Nichols W.T., Yates D.A., Streeter M.N., et al. Dose and release pattern of anabolic implants affects growth of finishing beef steers across days on feed. J Anim Sci 2011, 89(3):863-873.
21. Thompson S.H., Boxhorn L.K., Kong W.Y., Allen R.E. Trenbolone alters the responsiveness of skeletal muscle satellite cells to fibroblast growth factor and insulin-like growth factor I. Endocrinology 1989, 124(5):2110-2117.
22. Vernon B.G., Buttery P.J. Protein turnover in rats treated with trienbolone acetate. Br J Nutr 1976, 36(3):575-579.
23. Vernon B.G., Buttery P.J. The effect of trenbolone acetate with time on the various responses of protein synthesis of the rat. Br J Nutr 1978, 40(3):563-572.
24. Yarrow J.F., McCoy S.C., Borst S.E. Tissue selectivity and potential clinical applications of trenbolone (17beta-hydroxyestra-4,9,11-trien-3-one): A potent anabolic steroid with reduced androgenic and estrogenic activity. Steroids 2010, 75(6):377-389.
25. Pelker R.R., Friedlaender G.E., Markham T.C., Panjabi M.M., Moen C.J. Effects of freezing and freeze-drying on the biomechanical properties of rat bone. J Orthop Res 1984, 1(4):405-411.
26. Page S.T., Amory J.K., Bowman F.D., Anawalt B.D., Matsumoto A.M., Bremner W.J., et al. Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T. J Clin Endocrinol Metab 2005, 90(3):1502-1510.
27. Turner R.T., Colvard D.S., Spelsberg T.C. Estrogen inhibition of periosteal bone formation in rat long bones: down-regulation of gene expression for bone matrix proteins. Endocrinology 1990, 127(3):1346-1351.
28. Turner R.T., Lifrak E.T., Beckner M., Wakley G.K., Hannon K.S., Parker L.N. Dehydroepiandrosterone reduces cancellous bone osteopenia in ovariectomized rats. Am J Physiol 1990, 258(4 Pt 1):E673-E677.
29. Turner R.T., Wakley G.K., Hannon K.S. Differential effects of androgens on cortical bone histomorphometry in gonadectomized male and female rats. J Orthop Res 1990, 8(4):612-617.
30. Anderson F.H., Francis R.M., Selby P.L., Cooper C. Sex hormones and osteoporosis in men. Calcif Tissue Int 1998, 62(3):185-188.
31. Burge R., Dawson-Hughes B., Solomon D.H., Wong J.B., King A., Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res 2007, 22(3):465-475.
32. Higano C.S. Androgen-deprivation-therapy-induced fractures in men with nonmetastatic prostate cancer: what do we really know?. Nat Clin Pract Urol 2008, 5(1):24-34.
33. Warriner A.H., Patkar N.M., Curtis J.R., Delzell E., Gary L., Kilgore M., et al. Which fractures are most attributable to osteoporosis?. J Clin Epidemiol 2011, 64(1):46-53.
34. Sillence M.N., Rodway R.G. Effects of trenbolone acetate and testosterone on growth and on plasma concentrations of corticosterone and ACTH in rats. J Endocrinol 1990, 126(3):461-466.
35. Henneicke H., Herrmann M., Kalak R., Brennan-Speranza T.C., Heinevetter U., Bertollo N., et al. Corticosterone selectively targets endo-cortical surfaces by an osteoblast-dependent mechanism. Bone 2011, 49(4):733-742.
36. Broulik P.D., Broulikova K., Necas E. Progestagens androgenic action on the bone of male castrated mice. Prague Med Rep 2006, 107(4):401-408.
37. Vandenput L., Swinnen J.V., Boonen S., Van Herck E., Erben R.G., Bouillon R., et al. Role of the androgen receptor in skeletal homeostasis: the androgen-resistant testicular feminized male mouse model. J Bone Miner Res 2004, 19(9):1462-1470.
38. Vanderschueren D., Vandenput L. Androgens and osteoporosis. Andrologia 2000, 32(3):125-130.
39. Vanderschueren D., Vandenput L., Boonen S., Lindberg M.K., Bouillon R., Ohlsson C. Androgens and bone. Endocr Rev 2004, 25(3):389-425.
40. Vandenput L., Ohlsson C. Estrogens as regulators of bone health in men. Nat Rev Endocrinol 2009, 5(8):437-443.
41. Le Guevel R., Pakdel F. Assessment of oestrogenic potency of chemicals used as growth promoter by in-vitro methods. Hum Reprod 2001, 16(5):1030-1036.
42. Kasperk C.H., Wakley G.K., Hierl T., Ziegler R. Gonadal and adrenal androgens are potent regulators of human bone cell metabolism in vitro. J Bone Miner Res 1997, 12(3):464-471.
43. Wakley G.K., Schutte H.D., Hannon K.S., Turner R.T. Androgen treatment prevents loss of cancellous bone in the orchidectomized rat. J Bone Miner Res 1991, 6(4):325-330.
44. Bhasin S., Cunningham G.R., Hayes F.J., Matsumoto A.M., Snyder P.J., Swerdloff R.S., et al. Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2006, 91(6):1995-2010.
45. Bhasin S., Tenover J.S. Age-associated sarcopenia-issues in the use of testosterone as an anabolic agent in older men. J Clin Endocrinol Metab 1997, 82(6):1659-1660.
46. Bhasin S., Woodhouse L., Casaburi R., Singh A.B., Mac R.P., Lee M., et al. Older men are as responsive as young men to the anabolic effects of graded doses of testosterone on the skeletal muscle. J Clin Endocrinol Metab 2005, 90(2):678-688.
47. Borst S.E., Mulligan T. Testosterone replacement therapy for older men. Clin Interv Aging 2007, 2(4):561-566.
48. Shabsigh R., Crawford E.D., Nehra A., Slawin K.M. Testosterone therapy in hypogonadal men and potential prostate cancer risk: a systematic review. Int J Impot Res 2009, 21(1):9-23.
49. Lopez-Bote C., Sancho G., Martinez M., Ventanas J., Gazquez A., Roncero V. Trenbolone acetate induced changes in the genital tract of male pigs. Zentralbl Veterinarmed B 1994, 41(1):42-48.
50. Hotchkiss A.K., Nelson R.J. An environmental androgen, 17beta-trenbolone, affects delayed-type hypersensitivity and reproductive tissues in male mice. J Toxicol Environ Health A 2007, 70(2):138-140.
51. Fernandez-Balsells M.M., Murad M.H., Lane M., Lampropulos J.F., Albuquerque F., Mullan R.J., et al. Clinical review 1: Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab 2010, 95(6):2560-2575.
52. Jaillard A.S., Hommel M., Mazetti P. Prevalence of stroke at high altitude (3380 m) in Cuzco, a town of Peru. A population-based study. Stroke 1995, 26(4):562-568.
53. Kunnas T., Solakivi T., Huuskonen K., Kalela A., Renko J., Nikkari S.T. Hematocrit and the risk of coronary heart disease mortality in the TAMRISK study, a 28-year follow-up. Prev Med 2009, 49(1):45-47.
54. Price E.A., Mehra R., Holmes T.H., Schrier S.L. Anemia in older persons: etiology and evaluation. Blood Cells Mol Dis 2011, 46(2):159-165.
55. Costa E., Pereira B.J., Rocha-Pereira P., Rocha S., Reis F., Castro E., et al. Role of prohepcidin, inflammatory markers and iron status in resistance to rhEPO therapy in hemodialysis patients. Am J Nephrol 2008, 28(4):677-683.
56. Guralnik J.M., Eisenstaedt R.S., Ferrucci L., Klein H.G., Woodman R.C. Prevalence of anemia in persons 65 years and older in the United States: evidence for a high rate of unexplained anemia. Blood 2004, 104(8):2263-2268.
57. Artz A.S., Thirman M.J. Unexplained anemia predominates despite an intensive evaluation in a racially diverse cohort of older adults from a referral anemia clinic. J Gerontol A Biol Sci Med Sci 2011, 66(8):925-932.